Personnel Information

写真a

AI Masumi


Job title

Professor

Graduating School 【 display / non-display

  • Tokyo Medical and Dental University, Faculty of Medicine, School of Medicine, 1995.03, Graduated

Degree 【 display / non-display

  • MD,PhD, Tokyo Medical and Dental University

Campus Career 【 display / non-display

  • 2013.07
    -
    Now
    Tokyo Medical and Dental University, Medical Hospital, Department of Insured Medical Care Management, Director and Professor, Department of Insured Medical Care Management
  • 2013.10
    -
    Now
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Public Health, Insured Medical Care Management, Professor
  • 2013.05
    -
    2013.06
    Tokyo Medical and Dental University, Medical Hospital, Department of Insured Medical Care Management, Director, Department of Insured Medical Care Management
  • 2017.04
    -
    Now
    Tokyo Medical and Dental University, Medical Hospital, Director
  • 2018.08
    -
    Now
    Tokyo Medical and Dental University, Medical Hospital, Central Clinical Facilities, Medical Informatics, Director

display all >>

External Career 【 display / non-display

  • 2013.07
    -
    Now
    , Professor

Academic Society Affiliations 【 display / non-display

  • American Diabetes Association

  • American Heart Association

Research Areas 【 display / non-display

  • Metabolomics

  • Hygiene and public health

  • Laboratory medicine

  • Cardiovascular medicine

Qualification Acquired 【 display / non-display

  • Doctor

 

Research Theme 【 display / non-display

  • lipid metabolism, 1996.04 - Now

Published Papers & Misc 【 display / non-display

  • Kitazawa Toru, Seino Hiroaki, Ohashi Hiroshi, Inazawa Takeshi, Inoue Masahiro, Ai Masumi, Fujishiro Midori, Kuroda Hisamoto, Yamada Masayo, Anai Motonobu, Ishihara Hisamitsu. Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB) DIABETES OBESITY & METABOLISM. 2020.09; 22 (9): 1659-1663. ( PubMed, DOI )

  • Ikezaki H, Furusyo N, Yokota Y, Ai M, Asztalos BF, Murata M, Hayashi J, Schaefer EJ. Small Dense Low-Density Lipoprotein Cholesterol and Carotid Intimal Medial Thickness Progression. Journal of atherosclerosis and thrombosis. 2020.04; ( PubMed, DOI )

  • Hsu Hung, Hsu Powen, Cheng Ming-Hui, Ito Yasuki, Kanda Eiichiro, Schaefer Ernst J., Ai Masumi. 台湾における糖尿病前症および糖尿病におけるリポ蛋白質亜分画とグルコース恒常性(Lipoprotein Subfractions and Glucose Homeostasis in Prediabetes and Diabetes in Taiwan) Journal of Atherosclerosis and Thrombosis. 2019.10; 26 (10): 890-914. ( ichushi )

  • Ikezaki Hiroaki, Fisher Virginia A., Lim Elise, Ai Masumi, Liu Ching-Ti, Cupples L. Adrienne, Nakajima Katsuyuki, Asztalos Bela F., Furusyo Norihiro, Schaefer Ernst J.. Direct Versus Calculated LDL Cholesterol and C-Reactive Protein in Cardiovascular Disease Risk Assessment in the Framingham Offspring Study CLINICAL CHEMISTRY. 2019.09; 65 (9): 1102-1114. ( PubMed, DOI )

  • Kitazawa T., Seino H., Ohashi H., Inazawa T., Inoue M., Ai M., Fujishiro M., Kuroda H., Yamada M., Anai M., Ishihara H.. Tofogliflozin is a better candidate than glimepiride for the third line oral agent added to the metformin plus DPP-4 inhibitor dual therapy: results of a randomised control trial DIABETOLOGIA. 2019.09; 62 S359.

display all >>

Others 【 display / non-display

  • 2011.04

    IRB Member, Tokyo Institute of Technology 2011-2017

  • IRB Member, Sony Corporation 2012-